Ciba Performs Well But Hit By Currencies

4 September 1994

Swiss pharmaceutical and chemical group Ciba said that it has performed well in the first six months of 1994 but that currencies had a negative effect. Operating profits for the first half were ahead 19% in local currencies or 3% in Swiss francs at just over 2 billion Swiss francs ($1.55 billion). Net profits were 1.42 billion francs, flat in local currency and Swiss franc terms. Sales were 11.64 billion francs, up 3% in local currency terms and down 2% when expressed in Swiss francs.

The company said that it had a strong operational performance, but the weakening of all major currencies, except the yen, against the Swiss franc caused a negative currency effect of around 300 million francs.

In the agriculture sector conditions were said to have varied widely, and the industry sector is starting to enter into a recovery. The health care sector was said to have slowed in key markets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight